Market Overview

Merck Q2 Earnings Preview

Share:
Related MRK
The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding
Merck Or Pfizer: Which Is The Better Large-Cap Pharma Stock?
Pfizer facing difficult path to ramp up biosimilar business (Seeking Alpha)

Merck & Co (NYSE: MRK) releases its next round of earnings this Friday. Here's Benzinga's essential guide to Merck's Q2 earnings report.

Earnings and Revenue

Merck EPS will likely be near $1.03 while revenue will be around $10.29 billion, according to analysts.

In the same quarter last year, Merck posted EPS of $1.01 on sales of $9.93 billion. The Wall Street estimate would represent a 1.98 percent increase in the company's earnings. Sales would be up 3.63 percent on a year-over-year basis. Merck & Co's reported EPS has stacked up against analyst estimates in the past like this:

 

Quarter Q1 2018 Q4 2017 Q3 2017 Q2 2017
EPS Estimate 0.99 0.93 1.03 0.87
EPS Actual 1.05 0.98 1.11 1.01

Stock Performance

Over the last 52-week period, shares are up 3.07 percent. Given that these returns are generally positive, long-term shareholders can relax going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Analyst estimates have adjusted higher for EPS and revenues over the past 90 days. The average rating by analysts on Merck stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.

Posted-In: Earnings News

 

Related Articles (MRK)

View Comments and Join the Discussion!

Immunogen Earnings Preview

Samsung's 'Unbreakable' Smartphone Screen: What You Need To Know